Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex and multifaceted health ecosystem, and her goal of bringing together all healthcare stakeholders in much-needed dialogue on how to improve healthcare provision and efficiency.
Having a long and distinguished career on the other side of the table having led patient groups, what made you decide to assume the position of president of Innovative Medicines Canada, the innovative pharma industry association, in December 2016?
"When we are talking about addressing issues within the wider health systems, I believe all stakeholders need to be involved, and that includes industry."
